Magazine Article | February 1, 2017

Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules

By Gail Dutton, Contributing Editor
Follow Me On Twitter @GailLdutton

The Cuba trade embargo has almost ended, but American pharmaceutical companies have barely noticed. In a quick survey I did of 13 pharmaceutical companies ranging from Big Pharma to small generics manufacturers, plus two industry associations, all 15 organizations declined to comment about Cuba’s potential role in their business strategies or opportunities and challenges involved with doing business with that nation. Only one of those claimed the silence stemmed from competitive interests.

Two American organizations, however, are going on the record to discuss their work with Cuban researchers and their efforts to bring innovative research involving cancer vaccines and levels of consciousness (e.g., comas, brain death) to American patients.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.